Padagis Israel Pharmaceuticals Submits First-to-File ANDA for Generic Version of Roflumilast
The application for generic roflumilast cream, 0.3%, for plaque psoriasis may end up entitling Padagis to 180 days of market exclusivity.
Stay updated with breaking news from Sol Gel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The application for generic roflumilast cream, 0.3%, for plaque psoriasis may end up entitling Padagis to 180 days of market exclusivity.
Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, TWYNEO
To commemorate World Schizophrenia Awareness Day, we spoke to three researchers from the Queensland Brain Institiute about their research, and why it is so important to raise awareness around Schizophrenia
"We've been more comfortable with the idea of combination therapy for acne than we have been for rosacea," says Dr Julie Harper.
Pastures have turned to dust, wells have dried up, and increasing numbers of nomads are abandoning their self-sufficient, itinerant lives.